A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.
Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Inclusion Criteria:
Have had an established diagnosis of UC for ≥3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC.
Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline.
Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer.
Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]
Have overweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions:
Have an inadequate response to, loss of response to, or intolerance to at least 1 of the conventional medication: oral corticosteroids, oral azathioprine (AZA) or 6-mercaptopurine (6-MP), or oral 5-aminosalicylates (for example, mesalamine, sulfasalazine, olsalazine, and balsalazide) and/or who have an inadequate response to or a loss of response to, or are intolerant to advanced therapy for UC, defined as: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF) antibodies; anti-integrin antibodies, Janus kinase (JAK) inhibitors such as tofacitinib or upadacitinib, sphingosine 1-phosphate receptor 1inhibitors such as etrasimod or ozanimod, or anti-interleukin(IL)-12p40 antibodies, for example, ustekinumab.
Exclusion Criteria:
Have a current diagnosis of:
Have had or will need bowel resection or intestinal or intra-abdominal surgery.
Have evidence of toxic megacolon, or stricture or stenosis within the colon that cannot be traversed by a sigmoidoscope or colonoscope.
Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.
Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening.
Have a self-reported change in body weight greater than 5% (gain or reduction) within 3 months prior to screening.
Have a current or recent acute, active infection.
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Dothan, Alabama 36301, United States
334-836-1212
Miami, Florida 33134, United States
Fayetteville, North Carolina 28304, United States
Westlake, Ohio 44145, United States
Philadelphia, Pennsylvania 19107, United States
Liège, 4000, Belgium
Salvador, 41500-300, Brazil
Saint-Priest-en-Jarez, 42270, France
Bologna, 40138, Italy
Castellana Grotte, 70013, Italy
Ciudad Madero, 89440, Mexico
Durango, 34000, Mexico
Guadajalara, 44600, Mexico
3338306672
Guadalajara, 44340, Mexico
Mexico City, 14080, Mexico
Banská Bystrica, 97517, Slovakia
Ferrol, 15405, Spain
Ankara, 06560, Turkey (Türkiye)
310-423-4100
562-430-4449
818-349-1979
407-384-7388
208-528-4256
812-206-1702
502-888-1988
813-851-0135
318-525-3233
212-369-2490
215-955-8900
401-421-8800
864-451-5026
210-615-3848
210-581-2812
903-630-6211
253-272-5127
414-908-6500
4351250481311
004314040062450
053 72 44 28
003225555422
+32 56 63 33 00
+3216348856
+3243237256
+3243554211
+55 79 98825-9395
6134454300
19 3252-5611
+55 41 3322-1115
+5551999199815
1636022283
55 71 99957 2121
+55 11 2776-6801
551122713450
5511999158070
5527988393435
+5517997472217
519-685-8500
514-798-0550
+420607142114
00420602110107
+420 725 505 279
420477112450
0045 38681848
+4597663560
33467330224
01 41 43 05 73
33492039367
069630187769
02181475930
00493452997626
05115329427
00493414935720
004933124136202
+306976062713
2810392037
0036208250460
3612664616
+36302777114
+9720723398277
972-4-7772850
97235028500
+972 26666916
+97239377241 (5)
97235307072
+97236973011
972-8-934-9793
0512145312
+39 0804994379
0255032141
+390498217749
050997405
02 99430.3264
0630154678
0282243263
4493776500
+52 3339869435
4431478545
2229736952
52 55 53627780
2299327808
31205666545
+31 24 3619190
+317030792
0102975000
0031887573618
+48690143690
+48 724 444 299
618547552
604481752
48 91 433 29 19
500111648
48660551155
48606930022
0740182009
0213152590
0722546405
+40744761454
40751268731
0040722410712
421905838606
+421917752297
+421 905 271215
+421905794001
+34932746258
981 336871
985107878
848422391
0034955008800
961244055
0 505 319 22 57
902242951014
+90 505 782 38 08
0090 505 877 48 21
905326145276
01382 660111 ext 33118
07739858203